Central neuroprotection demonstrated by novel oxime countermeasures to nerve agent surrogates

• Published in: Annals of the New York Academy of Sciences Vol. 1479; no. 1; pp. 5 - 12
• Main Authors: Chambers, Janice E., Meek, Edward C.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.11.2020
• Subjects: Acetylcholinesterase; Acetylcholinesterase - metabolism; Animals; Antidotes - therapeutic use; Brain; brain protection; Cholinergics; Glial fibrillary acidic protein; GPI-Linked Proteins - metabolism; Laboratories; Lethal levels; Lethality; Male; nerve agent surrogates; Nerve agents; Nerve Agents - toxicity; Neuroprotection; Neuroprotection - drug effects; novel oximes; Organophosphates; Organothiophosphorus Compounds - toxicity; Oximes; Pralidoxime Compounds - therapeutic use; Pyridinium; Rats; Recovery of function; Sarin; Sarin - toxicity; Scars; Seizures; Toxicity; United States; United States; brain protection; novel oximes; nerve agent surrogates; neuroprotection

Oximes remain a long‐standing element of the therapy for nerve agents, organophosphates (OPs) that poison by inhibiting the enzyme acetylcholinesterase (AChE), resulting in hypercholinergic activity both centrally and peripherally. Oximes, such as the pyridinium oxime pralidoxime (2‐PAM) in the Unit...